179 related articles for article (PubMed ID: 36447830)
21. Recovery of bone mineralization and quality during asfotase alfa treatment in an adult patient with infantile-onset hypophosphatasia.
Rolvien T; Schmidt T; Schmidt FN; von Kroge S; Busse B; Amling M; Barvencik F
Bone; 2019 Oct; 127():67-74. PubMed ID: 31152801
[TBL] [Abstract][Full Text] [Related]
22. ALPL Genotypes in Patients With Atypical Femur Fractures or Other Biochemical and Clinical Signs of Hypophosphatasia.
Marini F; Masi L; Giusti F; Cianferotti L; Cioppi F; Marcucci G; Ciuffi S; Biver E; Toro G; Iolascon G; Iantomasi T; Brandi ML
J Clin Endocrinol Metab; 2022 Apr; 107(5):e2087-e2094. PubMed ID: 34935951
[TBL] [Abstract][Full Text] [Related]
23. Hypermobile Ehlers-Danlos syndrome (a.k.a. Ehlers-Danlos syndrome Type III and Ehlers-Danlos syndrome hypermobility type): Clinical description and natural history.
Tinkle B; Castori M; Berglund B; Cohen H; Grahame R; Kazkaz H; Levy H
Am J Med Genet C Semin Med Genet; 2017 Mar; 175(1):48-69. PubMed ID: 28145611
[TBL] [Abstract][Full Text] [Related]
24. Effect of Asfotase Alfa on Muscle Weakness in a Japanese Adult Patient of Hypophosphatasia with Low ALP Levels.
Koyama H; Yasuda S; Kakoi S; Ohata Y; Shimizu Y; Hasegawa C; Hayakawa A; Akiyama T; Yagi T; Aotani D; Imaeda K; Ozono K; Kataoka H; Tanaka T
Intern Med; 2020 Mar; 59(6):811-815. PubMed ID: 31787692
[TBL] [Abstract][Full Text] [Related]
25. Monitoring guidance for patients with hypophosphatasia treated with asfotase alfa.
Kishnani PS; Rush ET; Arundel P; Bishop N; Dahir K; Fraser W; Harmatz P; Linglart A; Munns CF; Nunes ME; Saal HM; Seefried L; Ozono K
Mol Genet Metab; 2017 Sep; 122(1-2):4-17. PubMed ID: 28888853
[TBL] [Abstract][Full Text] [Related]
26. Urine phosphoethanolamine is a specific biomarker for hypophosphatasia in adults.
Shajani-Yi Z; Ayala-Lopez N; Black M; Dahir KM
Bone; 2022 Oct; 163():116504. PubMed ID: 35878747
[TBL] [Abstract][Full Text] [Related]
27. Odontohypophosphatasia treated with asfotase alfa enzyme replacement therapy in a toddler: a case report.
Takagi M; Kato S; Muto T; Sano Y; Akiyama T; Takagi J; Okumura A; Iwayama H
Clin Pediatr Endocrinol; 2020; 29(3):115-118. PubMed ID: 32694888
[TBL] [Abstract][Full Text] [Related]
28. Excellent response to asfotase alfa treatment in an adolescent patient with hypophosphatasia.
Strandbech OS; Lund A; Ostergaard E
JIMD Rep; 2021 May; 59(1):10-15. PubMed ID: 33977024
[TBL] [Abstract][Full Text] [Related]
29. Bilateral atypical femoral fractures during denosumab therapy in a patient with adult-onset hypophosphatasia.
Warren AM; Ebeling PR; Grill V; Seeman E; Sztal-Mazer S
Endocrinol Diabetes Metab Case Rep; 2021 Sep; 2021():. PubMed ID: 34515659
[TBL] [Abstract][Full Text] [Related]
30. Impact of pediatric hypophosphatasia on behavioral health and quality of life.
Pierpont EI; Simmons JH; Spurlock KJ; Shanley R; Sarafoglou KM
Orphanet J Rare Dis; 2021 Feb; 16(1):80. PubMed ID: 33579333
[TBL] [Abstract][Full Text] [Related]
31. Redefining the progeroid form of Ehlers-Danlos syndrome: report of the fourth patient with B4GALT7 deficiency and review of the literature.
Guo MH; Stoler J; Lui J; Nilsson O; Bianchi DW; Hirschhorn JN; Dauber A
Am J Med Genet A; 2013 Oct; 161A(10):2519-27. PubMed ID: 23956117
[TBL] [Abstract][Full Text] [Related]
32. Pathophysiology of hypophosphatasia and the potential role of asfotase alfa.
Orimo H
Ther Clin Risk Manag; 2016; 12():777-86. PubMed ID: 27274262
[TBL] [Abstract][Full Text] [Related]
33. Hypophosphatasia in Adults: Clinical Assessment and Treatment Considerations.
Shapiro JR; Lewiecki EM
J Bone Miner Res; 2017 Oct; 32(10):1977-1980. PubMed ID: 28731215
[TBL] [Abstract][Full Text] [Related]
34. Alkaline Phosphatase Replacement Therapy for Hypophosphatasia in Development and Practice.
Bowden SA; Foster BL
Adv Exp Med Biol; 2019; 1148():279-322. PubMed ID: 31482504
[TBL] [Abstract][Full Text] [Related]
35. Hypophosphatasia: presentation and response to asfotase alfa.
Alsarraf F; Ali DS; Almonaei K; Al-Alwani H; Khan AA; Brandi ML
Osteoporos Int; 2024 Apr; 35(4):717-725. PubMed ID: 37993691
[TBL] [Abstract][Full Text] [Related]
36. Hypophosphatasia: A Unique Disorder of Bone Mineralization.
Villa-Suárez JM; García-Fontana C; Andújar-Vera F; González-Salvatierra S; de Haro-Muñoz T; Contreras-Bolívar V; García-Fontana B; Muñoz-Torres M
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33919113
[TBL] [Abstract][Full Text] [Related]
37. Asfotase alfa has a limited effect in improving the bowed limbs in perinatal benign hypophosphatasia: A case report.
Matsushita M; Mishima K; Nagata T; Kamiya Y; Imagama S; Kitoh H
Clin Pediatr Endocrinol; 2021; 30(1):53-56. PubMed ID: 33446953
[TBL] [Abstract][Full Text] [Related]
38. Glycosaminoglycan linkage region of urinary bikunin as a potentially useful biomarker for β3GalT6-deficient spondylodysplastic Ehlers-Danlos syndrome.
Nikpour M; Noborn F; Nilsson J; Van Damme T; Kaye O; Syx D; Malfait F; Larson G
JIMD Rep; 2022 Sep; 63(5):462-467. PubMed ID: 36101818
[TBL] [Abstract][Full Text] [Related]
39. Hypophosphatasia: Current Literature for Pathophysiology, Clinical Manifestations, Diagnosis, and Treatment.
Bangura A; Wright L; Shuler T
Cureus; 2020 Jun; 12(6):e8594. PubMed ID: 32676235
[TBL] [Abstract][Full Text] [Related]
40. Extracutaneous features and complications of the Ehlers-Danlos syndromes: A systematic review.
Doolan BJ; Lavallee ME; Hausser I; Schubart JR; Michael Pope F; Seneviratne SL; Winship IM; Burrows NP
Front Med (Lausanne); 2023; 10():1053466. PubMed ID: 36756177
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
